Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Integrum AB (publ)
  6. News
  7. Summary
    INTEG B   SE0009807266

INTEGRUM AB (PUBL)

(INTEG B)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-09-23 am EDT
27.65 SEK   -9.05%
09/13Oslo University Hospital diversifies its patient offering and scales up the use of Integrum's OPRA Implant System
AQ
09/13Oslo University Hospital Diversifies Its Patient Offering and Scales Up the Use of Integrum AB's Opra Implant System
CI
09/08Integrum's CEO Rickard Brånemark presents at a leading conference of limb salvage in US
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Integrum appoints Rickard Brňnemark as new CEO

05/19/2022 | 12:23pm EDT

Mölndal, Sweden, May 19, 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the Board of Directors has appointed Rickard Brånemark as CEO of the company. Rickard Brånemark has simultaneously resigned as Chairman of the Board.

Dr. Brånemark is the founder and main owner of Integrum AB and was CEO between 1998-2015. He has pioneered studies of titanium implants to anchor limb prostheses for more than 20 years. As the most experienced surgeon in the field, Dr. Brånemark is internationally recognized for his contributions to amputation treatment research and development. He is currently Research Scientist at MIT, Massachusetts, USA. He has been a member of the board since 2009.

The Board of Directors has appointed Rickard Brånemark as CEO on a full-time basis, effective immediately. Simultaneously, Rickard Brånemark resigned as Chairman of the Board, and the Board of Directors appointed Bengt Sjöholm as new Chairman. Bengt Sjöholm has a vast experience from the medtech industry and has served as Board Director since 2019.

Integrum's previous CEO, Maria Elena Lopez, will continue to support the company during the termination period.

"Since I founded this company with my father in 1998, I have been highly engaged in its development. I am an entrepreneur by heart, and as the company now enters an intense phase of strong commercial growth where our efforts to establish our OPRATM Implant System as the new standard of care are starting to pay off, I welcome this opportunity to lead the company and its many talented employees. I want to sincerely thank Maria Elena Lopez for her extraordinary achievements during the last years, not least her strong contributions during the difficult times of the pandemic and the successful process of our adaption to the new MDR regulation", comments Rickard Brånemark.   

"As the healthcare systems now reopen after the Covid-19-pandemic, Integrum can fully focus on growth. We appreciate that Rickard Brånemark has accepted the role as CEO, yet another sign of his long-term commitment to the company. His experience, strong commercial drive, and extensive global network will serve the company and its shareholders well during the next phase of the company's development", comments Bengt Sjöholm, Chairman of the Board.

Rickard Brånemark is currently resident in the United States and the Swedish Companies Registration Office's registration of him as CEO requires that the Swedish Companies Registration Office grant an exemption from the so called residency requirement stated in the Swedish Companies Act (2005:551), meaning that the CEO must be resident in the European Economic Area. In the event that the Swedish Companies Registration Office denies the application for exemption, the Board will consider possible alternative measures in order for Rickard to be appointed.

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2022-05-19 18:22 CET.

Rickard Brånemark, CEO. Phone: +46 708 461061, E-mail: rickard.branemark@integrum.se

Bengt Sjöholm, Chairman of the Board, Phone: + 46 705 313811, E-mail: bengt.sjoholm@bsjab.se

Dennis Baecklund, CFO. Phone: +46 (0) 72 556 68 69, E-mail: dennis.baecklund@integrum.se

Certified Adviser

Erik Penser Bank is Certified Adviser and can be reached at +46 (0) 8-463 8000.

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum's system for bone-anchored prostheses - a vastly superior alternative to the traditionally used socket prosthesis

https://news.cision.com/integrum-ab/r/integrum-appoints-rickard-branemark-as-new-ceo,c3571068

https://mb.cision.com/Main/17531/3571068/1582343.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about INTEGRUM AB (PUBL)
09/13Oslo University Hospital diversifies its patient offering and scales up the use of Inte..
AQ
09/13Oslo University Hospital Diversifies Its Patient Offering and Scales Up the Use of Inte..
CI
09/08Integrum's CEO Rickard Brånemark presents at a leading conference of limb salvage in US
AQ
09/01Integrum Q1 - Continuing on the positive trajectory
AQ
08/31INTERIM REPORT MAY - JUL 2022 : Steady sales growth fuelled by increased market penetratio..
AQ
08/31Integrum AB Reports Earnings Results for the First Quarter Ended July 31, 2022
CI
06/14Integrum - Solid performance in Q4
AQ
06/13Integrum expands and relocates to GoCo Health Innovation City
AQ
06/13Integrum AB Announces Address Change of Headquarters
CI
06/10Integrum AB Reports Earnings Results for the Fourth Quarter and Full Year Ended April 3..
CI
More news
Financials
Sales 2023 110 M 9,78 M 9,78 M
Net income 2023 -6,00 M -0,53 M -0,53 M
Net cash 2023 49,0 M 4,35 M 4,35 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 504 M 44,8 M 44,8 M
EV / Sales 2023 4,13x
EV / Sales 2024 2,84x
Nbr of Employees 32
Free-Float 54,2%
Chart INTEGRUM AB (PUBL)
Duration : Period :
Integrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 27,65 SEK
Average target price 104,00 SEK
Spread / Average Target 276%
EPS Revisions
Managers and Directors
Rickard Brňnemark Chief Executive Officer
Dennis Baecklund Chief Financial Officer
Bengt Sj÷holm Chairman
Magnus Lindholm Manager-Research & Development
Karin Ganl÷v Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
INTEGRUM AB (PUBL)-61.60%45
STRAUMANN HOLDING AG-54.10%14 448
SONOVA HOLDING AG-40.16%13 350
COCHLEAR LIMITED-9.05%8 462
DEMANT A/S-42.29%5 574
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.-16.88%2 579